Ustekinumab in Crohn's disease: real-world outcomes and predictors of response. | Zendy

Laura Lorenzo González | Zendy; Teresa Valdés Delgado | Zendy; Juan María Vázquez Morón | Zendy; Luisa Castro Laria | Zendy; Eduardo Leo Carnerero | Zendy; María Belén Maldonado Pérez | Zendy; Antonio Damián Sánchez-Capilla | Zendy; Héctor Pallarés Manrique | Zendy; Antonia Sáez Díaz | Zendy; Federico ArgüellesArias | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.

Author(s) -

Laura Lorenzo González,

Teresa Valdés Delgado,

Juan María Vázquez Morón,

Luisa Castro Laria,

Eduardo Leo Carnerero,

María Belén Maldonado Pérez,

Antonio Damián Sánchez-Capilla,

Héctor Pallarés Manrique,

Antonia Sáez Díaz,

Federico ArgüellesArias

Publication year - 2020

Publication title -

revista española de enfermedades digestivas

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.331

H-Index - 38

eISSN - 2340-4167

pISSN - 1130-0108

DOI - 10.17235/reed.2020.7352/2020

Subject(s) - ustekinumab , medicine , crohn's disease , observational study , gastroenterology , ulcerative colitis , disease , vedolizumab , adalimumab

ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the treatment of Crohn's disease (CD) and, more recently, also ulcerative colitis (UC). The aim of this study was to evaluate the effectiveness and safety of ustekinumab, as well as to identify possible predictive factors of response in a real-life setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research